0.00
price down icon100.00%   -0.0949
 
loading
AIM ImmunoTech Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.0949
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.52M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
0.00
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$0.469

AIM ImmunoTech Inc Stock (AIM) Company Profile

Name
Name
AIM ImmunoTech Inc
Name
Phone
352 448 7797
Name
Address
2117 SW Highway 484, Ocala, FL
Name
Employee
24
Name
Twitter
@AIMImmuno
Name
Next Earnings Date
2024-12-15
Name
Latest SEC Filings
Name
AIM's Discussions on Twitter

Compare AIM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AIM
AIM ImmunoTech Inc
0.00 6.52M 202.00K -28.96M -21.85M -0.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

AIM ImmunoTech Inc Stock (AIM) Latest News

pulisher
Apr 25, 2025

AIM ImmunoTech files to sell units, no amount given - MSN

Apr 25, 2025
pulisher
Apr 15, 2025

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail

Apr 15, 2025
pulisher
Apr 13, 2025

AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com

Apr 13, 2025
pulisher
Apr 12, 2025

AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN

Apr 12, 2025
pulisher
Apr 10, 2025

AIM ImmunoTech appoints Chemerow as an Independent Director - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

AIM ImmunoTech Changes Markets: Key Details of AIMI Ticker Switch and Special Meeting - Stock Titan

Apr 07, 2025
pulisher
Apr 05, 2025

Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com Australia

Apr 05, 2025
pulisher
Apr 05, 2025

Aim Immunotech’s COO Peter Rodino III acquires shares for $43 By Investing.com - Investing.com India

Apr 05, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech faces NYSE American delisting over low stock price By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech announces NYSE American notice of delisting and appeal - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - marketscreener.com

Apr 04, 2025
pulisher
Apr 04, 2025

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire

Apr 04, 2025
pulisher
Apr 04, 2025

Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 03, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada

Apr 02, 2025
pulisher
Apr 01, 2025

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire

Apr 01, 2025
pulisher
Apr 01, 2025

AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 31, 2025
pulisher
Mar 28, 2025

Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings Preview For AIM ImmunoTech - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Inc. (AIM) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan

Mar 27, 2025
pulisher
Mar 19, 2025

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World

Mar 18, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News

Mar 06, 2025
pulisher
Mar 05, 2025

Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India

Mar 05, 2025

AIM ImmunoTech Inc Stock (AIM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):